The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Anti-vascular endothelial growth factor (VEGF) treatments show great promise in the treatment
of a variety of retinal diseases. This study addresses a condition which affects a large
number of our patients in whom the investigators face difficult management decisions. These
patients with uveitis are severely disabled with visual loss related to cystoid macular
oedema (CMO) and few options remain when standard treatment has either failed or is
contraindicated.
The concentration of VEGF is increased in the eyes of patients with uveitis. Our hypothesis
is that a series of injections of Ranibizumab may be an effective treatment for CMO. It is
hoped that anti-VEGF therapy will have fewer side-effects than existing therapies and will be
more effective in improving quality of life by reducing macular thickening and restoring
visual function.